Researchers at the University of Wisconsin–Madison have developed a method to simplify the formation of carbon–nitrogen (C–N) bonds, a fundamental step in producing amines widely used in pharmaceuticals, agrochemicals and advanced materials.

The global market for branded generics is expanding rapidly, reflecting mounting pressure on healthcare systems to contain costs while maintaining patient confidence in treatment quality.

US President Donald Trump has announced a pricing agreement with Regeneron Pharmaceuticals, marking the final deal in a series of negotiations between the administration and leading drugmakers aimed at lowering the cost of medicines in the US.

South Korea has consolidated its position as a leading player in pharmaceutical innovation, ranking third globally for drug development pipelines in 2026, behind only the US and China, according to industry data.

Eli Lilly has declined to list its diabetes treatment Mounjaro on Australia’s Pharmaceutical Benefits Scheme (PBS), despite a recommendation from the country’s medicines regulator, citing what it described as an unacceptably low pricing proposal from the federal government.

Analysts are looking ahead to the tafamidis patent trial involving Pfizer (NYSE: PFE), as recent court developments begin to shape investor expectations ahead of the proceedings next week.

Amneal Pharmaceuticals (AMRX) has agreed to acquire Kashiv BioSciences in a cash-and-stock transaction worth up to $1.1bn, in a move that will significantly expand the New Jersey drugmaker's position in the fast-growing biosimilars market.

The war in Iran has pushed up the retail price of widely used over-the-counter medicines in England by as much as 30 per cent, with pharmacists warning that further increases are likely unless key supply routes reopen.

AbbVie (ABBV) is to invest $1.4bn in a 185-acre pharmaceutical manufacturing campus in Durham, North Carolina, the company's largest single capital investment to date and its first significant foray into the state.

Adial Pharmaceuticals, the US clinical-stage biotech developing therapies for addiction disorders, has completed a demonstration manufacturing batch for its lead drug candidate AD04, clearing a technical prerequisite for the production of clinical and registration batches ahead of a planned phase 3 trial.

Europe faces a defining test of its ability to secure access to the latest innovative medicines, the head of the European Medicines Agency has warned, as US pricing policy pushes drugmakers to rethink where, when and at what price they bring new therapies to market.

Heights Capital Management, the San Francisco-based investment firm, has disclosed a 25.44 per cent stake in Faron Pharmaceuticals, the Finnish biotech, cementing its position as a dominant financial backer of the loss-making drug developer through a combination of direct shareholdings and convertible debt.

Pfizer is heading into one of the most consequential pharmaceutical patent battles of 2026 as the US drugmaker prepares to defend the intellectual property underpinning its tafamidis franchise, the cornerstone of its presence in the fast-growing market for transthyretin amyloid cardiomyopathy.

Improved Pharma, the West Lafayette-based pharmaceutical research and consulting group, will present new work on detecting crystalline impurities in amorphous drug formulations at the Spring Pharmaceutical Synchrotron-XRPD Workshop in Basel next month, as the industry continues to grapple with one of the more persistent shelf-life risks in modern drug development.

Belpointe Asset Management has opened a new position in Regeneron Pharmaceuticals worth approximately $1.74mn, according to the latest quarterly regulatory filing from the Reno-based investment manager, in the latest sign of renewed institutional interest in the US biotech group.

Shares in Agios Pharmaceuticals fell 25 per cent on Monday after Danish pharmaceutical group Novo Nordisk unveiled encouraging clinical data for its experimental sickle cell disease therapy, intensifying competitive pressure on the Boston-based biotech's own late-stage programme in the same indication.

OliX Pharmaceuticals, the Seoul-listed RNA interference specialist, has signed a memorandum of understanding with Galux, a South Korean artificial-intelligence drug discovery firm, to co-develop a new class of siRNA delivery platform — the latest tie-up between Korean biotech and AI design players as the industry races to broaden the reach of gene-silencing medicines beyond the liver.

Amazon Filters, the Surrey-based process filtration manufacturer, will use this week's ISPE Europe Annual Conference in Copenhagen to pitch its sanitary filtration systems to pharmaceutical and biopharmaceutical buyers, in a bid to deepen its foothold in one of the most demanding segments of the global life sciences supply chain.

NEUVIOR Pharmaceuticals, a York-based start-up, has secured a feasibility grant from Innovate UK to develop a process for converting pharmaceutical manufacturing waste into bio-based, recyclable materials, in the latest sign of mounting state support for circular-economy innovation in the UK life sciences sector.

Alamar Biosciences, a medical devices company that detects protein biomarkers for disease diagnosis, has raised $191mn in an upsized initial public offering on the Nasdaq, pricing at the top of its marketed range as investor appetite for healthcare listings shows signs of revival.